Please use this identifier to cite or link to this item: https://repositorio.uca.edu.ar/handle/123456789/1441
Título : Integrin avB3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells
Autor : Cayrol, María Florencia 
Díaz Flaqué, María Celeste 
Tharu, Fernando 
Yang, Shao Ning 
Sterle, Helena Andrea 
Bolontrade, Marcela 
Amorós, Mariana 
Isse, Blanca 
Farías, Ricardo Norberto 
Haelee, Ahn 
Tian, Ye F. 
Tabbò, Fabrizio 
Singh, Ankur 
Inghirami, Giorgio 
Cerchietti, Leandro 
Cremaschi, Graciela A. 
Palabras clave : BIOLOGIAMEDICINATUMORESGLANDULA TIROIDESHORMONAS
Fecha de publicación : 2015
Editorial : American Society of Hematology
Cita : Cayrol, F, Díaz Flaqué, MC, Tharu, F, et al. Integrin avB3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells [en línea]. Blood 2015;125(5):841-851. Disponible en: http://www.bloodjournal.org/content/bloodjournal/125/5/841.full.pdf [Fecha de consulta: ….] Registro disponible en: http://bibliotecadigital.uca.edu.ar/greenstone/cgi-bin/library.cgi?a=d&c=investigacion&d=integrin-acting-membrane-receptor-thyroid
Resumen : Abstract: The interaction of lymphoid tumor cells with components of the extracellular matrix via integrin avb3 allows tumor survival and growth. This integrin was demonstrated to be the membrane receptor for thyroid hormones (THs) in several tissues. We found that THs, acting as soluble integrin avb3 ligands, activated growth-related signaling pathways in T-cell lymphomas (TCLs). Specifically, TH-activated avb3 integrin signaling promoted TCL proliferation and angiogenesis, in part, via the upregulation of vascular endothelial growth factor (VEGF). Consequently, genetic or pharmacologic inhibition of integrin avb3 decreased VEGF production and induced TCL cell death in vitro and in human xenograft models. In sum, weshowthat integrin avb3 transduces prosurvival signals into TCL nuclei, suggesting a novel mechanism for the endocrine modulation of TCL pathophysiology. Targeting this mechanism could constitute an effective and potentially low-toxicity chemotherapy-free treatment of TCL patients.
URI : https://repositorio.uca.edu.ar/handle/123456789/1441
ISSN : 0006-4971
Disciplina: MEDICINA
DOI: 10.1182/blood-2014-07-587337
Derechos: Acceso Abierto
Appears in Collections:Artículos

Files in This Item:
File Description SizeFormat
841.full.pdf2,59 MBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

52
checked on Oct 20, 2020

Download(s)

48
checked on Oct 20, 2020

Google ScholarTM

Check


Altmetric


This item is licensed under a Creative Commons License Creative Commons